Arbutus Biopharma (ABUS) Asset Writedowns and Impairment (2015 - 2019)

Arbutus Biopharma (ABUS) has reported Asset Writedowns and Impairment for 5 consecutive years, with $43.8 million the latest figure, recorded in Q3 2019.

• Quarterly Asset Writedowns and Impairment rose 195.97% year-over-year to $43.8 million in Q3 2019, while the trailing twelve-month figure through Dec 2020 was $43.8 million (down 25.25% YoY) and the FY2019 annual result came in at $43.8 million, up 195.97% from the prior year.
• Asset Writedowns and Impairment grew to $43.8 million in Q3 2019 per ABUS's latest filing, from $14.8 million in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for ABUS reached as high as $156.3 million in Q2 2016 and fell as low as $1.0 million in Q4 2015.
• A 5-year average of $55.9 million and a median of $40.8 million in 2017 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2016 — Asset Writedowns and Impairment surged 9425.37% — and 2017, when it slumped 57.89%.
• Year by year, Asset Writedowns and Impairment stood at $1.0 million in 2015, then jumped by 9425.37% to $96.9 million in 2016, then sank by 57.89% to $40.8 million in 2017, then slumped by 63.7% to $14.8 million in 2018, then jumped by 195.97% to $43.8 million in 2019.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $43.8 million, $14.8 million, and $40.8 million for Q3 2019, Q3 2018, and Q4 2017 respectively.